thromboxanes has been researched along with molsidomine in 7 studies
| Studies (thromboxanes) | Trials (thromboxanes) | Recent Studies (post-2010) (thromboxanes) | Studies (molsidomine) | Trials (molsidomine) | Recent Studies (post-2010) (molsidomine) |
|---|---|---|---|---|---|
| 3,202 | 149 | 199 | 2,022 | 148 | 143 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (57.14) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beisiegel, B; Darius, H; Erbel, R; Hafner, G; Meyer, J; Pop, T; Rupprecht, HJ; Treese, N | 1 |
| Bordet, JC; Croset, M; Lagarde, M | 1 |
| Bordet, JC; Lagarde, M | 1 |
| Levy-Toledano, S; Maclouf, J; Rendu, F; Weill, D | 1 |
| Block, HU; Förster, W; Heinroth, I | 1 |
| Schrör, K; Strobach, H; Weber, AA | 1 |
| Bode-Böger, SM; Böger, RH; Frölich, JC; Galland, A | 1 |
2 trial(s) available for thromboxanes and molsidomine
| Article | Year |
|---|---|
[Modification of thrombocyte function in diagnostic and therapeutic interventions in cardiology].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Exercise Test; Fibrinolysis; Follow-Up Studies; Humans; Molsidomine; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Recurrence; Thromboxanes; Tissue Plasminogen Activator | 1991 |
Differential inhibition of human platelet aggregation and thromboxane A2 formation by L-arginine in vivo and in vitro.
Topics: Adult; Antithrombins; Arginine; Blood Platelets; Cyclic GMP; Enzyme Inhibitors; Humans; In Vitro Techniques; Infusions, Intravenous; Male; Molsidomine; Nitric Oxide Synthase; Platelet Aggregation; Platelet Aggregation Inhibitors; Thromboxane A2; Thromboxane B2; Thromboxanes | 1998 |
5 other study(ies) available for thromboxanes and molsidomine
| Article | Year |
|---|---|
Differential effect of SIN-1 on thromboxane and prostacyclin formation in platelets and endothelial cells.
Topics: Arachidonic Acids; Blood Platelets; Cells, Cultured; Endothelium, Vascular; Epoprostenol; Humans; Molsidomine; Oxygen Consumption; Thromboxanes; Umbilical Veins; Vasodilator Agents | 1989 |
Modulation of prostacyclin/thromboxane formation by molsidomine during platelet-endothelial cell interactions.
Topics: Arachidonic Acid; Arachidonic Acids; Blood Platelets; Cell Communication; Cells, Cultured; Endothelium, Vascular; Epoprostenol; Humans; Molsidomine; Thromboxanes | 1988 |
[Effects of SIN-1 on the early phases of blood platelet activation].
Topics: Blood Platelets; Humans; Molsidomine; Platelet Aggregation; Serotonin; Thromboxanes | 1987 |
SIN-1, the main metabolite of molsidomine, inhibits prostaglandin endoperoxide analogue- and arachidonic acid-induced platelet aggregation as well as platelet thromboxane A2 formation.
Topics: Animals; Arachidonic Acids; Blood Platelets; Drug Interactions; Female; Humans; Indoles; Male; Molsidomine; Oxadiazoles; Platelet Aggregation; Prostaglandin Endoperoxides, Synthetic; Pyridines; Rabbits; Sydnones; Thromboxane A2; Thromboxanes | 1982 |
Direct inhibition of platelet function by organic nitrates via nitric oxide formation.
Topics: Adenosine Triphosphate; Animals; Anisotropy; Blood Platelets; Cells, Cultured; Cyclic GMP; Dose-Response Relationship, Drug; Esters; Fibroblasts; Humans; Lung; Molsidomine; Nitrates; Nitric Oxide; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Thromboxanes | 1993 |